Podcasts about Pancreatic cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPE865. CME/NCPD/AAPA/IPCE credit will be available until July 13, 2027.Restructuring Clinical Care Models in Pancreatic Cancer: Expert Guidance on Improving Patient Outcomes With Modern Therapeutic Strategies in Community Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPE865. CME/NCPD/AAPA/IPCE credit will be available until July 13, 2027.Restructuring Clinical Care Models in Pancreatic Cancer: Expert Guidance on Improving Patient Outcomes With Modern Therapeutic Strategies in Community Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPE865. CME/NCPD/AAPA/IPCE credit will be available until July 13, 2027.Restructuring Clinical Care Models in Pancreatic Cancer: Expert Guidance on Improving Patient Outcomes With Modern Therapeutic Strategies in Community Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPE865. CME/NCPD/AAPA/IPCE credit will be available until July 13, 2027.Restructuring Clinical Care Models in Pancreatic Cancer: Expert Guidance on Improving Patient Outcomes With Modern Therapeutic Strategies in Community Settings In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

Pancreatic cancer has long been considered a death sentence. But a revolutionary new treatment has been shown to double survival times. *** Thank you for listening. Help power On Point by making a donation here: wbur.org/giveonpoint

Clinical trial support companies are rapidly adopting AI, but sponsors have been more hesitant. Raj Indupuri, CEO of eClinical Solutions, gives the top three reasons behind the holdup in AI agent deployment. He explains the specific pattern of uptake for these agents, the required human-in-the-loop oversight, and how the agents can improve clinical trial velocity. Host Deborah Borfitz also gives the latest news on a highly acclaimed treatment for pancreatic cancer, filling evidence gaps in drug safety during pregnancy, guidelines for routinely collected health data for research purposes, an innovative portal aiding bidirectional communication with patients, and more. Show Notes News Roundup KRAS inhibitor therapy for pancreatic cancer Study in The New England Journal of Medicine  News on the Fred Hutch Cancer Center website  Target trial emulation in rural areas Perspective in the Medical Journal of Australia News on the Griffith University website   AI for improving drug safety during pregnancy Report from the Journal of Medical Internet Research Guidelines on the use of routinely collected data Article in The BMJ New regulatory framework in the U.K. Press release by the Medicines and Healthcare products Regulatory Agency  Participant Engagement Portal Article in JNCI Cancer Spectrum Press release from the Alliance for Clinical Trials in Oncology The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.  

Kira Andersen's life took a drastic turn when her husband, Kyle, was diagnosed with stage four pancreatic cancer shortly after the birth of their third child. Refusing to accept a grim prognosis, Kira leveraged her background in medical and pharmaceutical sales to advocate for experimental treatments, securing "compassionate use" for a promising inhibitor. This intervention, now known as the "Kyle Anderson Regimen," granted their family an extra year of life together and is now saving other stage four patients. Today, Kira honors his memory by hosting the "Yes We Can" podcast and continuing a relentless mission to raise the final $1 million of a $3 million goal for targeted research at Siteman Cancer Center.

In this episode, we review the high-yield topic of ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Pancreatic Cancer⁠⁠⁠⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

What happens when a sudden diagnosis gives you only months to live? In this episode of Everyone Dies, we explore what it means to live fully on the threshold of life's final chapters.  https://bit.ly/4ezL0FCFirst, we share the deeply moving, self-written obituary of Nora Patricia Keenan, who passed away from complications of colorectal cancer. With unapologetic honesty, Nora looks back at her journey through chaos, addiction, recovery, and growth, reminding us that a meaningful life isn't about being spotless—it's about being honest and showing up. Then, we dive into a powerful discussion about former Nebraska Senator and University of Florida President Ben Sasse, who was diagnosed with Stage IV pancreatic cancer. Then, we dive into a powerful discussion about former Nebraska Senator and University of Florida President Ben Sasse, who was diagnosed with Stage IV pancreatic cancer. Sasse shared a raw look at how a terminal diagnosis brings acute clarity, his experience on a targeted clinical trial, and how he is spending his limited time with his wife and three children.We close the episode with a beautiful reading of Rev. Henry Scott Holland's classic poem, "Death Is Nothing at All." Timestamps00:00 – Introduction:  Honesty, Grit, and Redeeming the Time 02:18 – Recipe of the Week: Disappearing Dip 02:45 – Nora Patricia Keenan's Incredible Self-Written Obituary 05:46 – Living on the Threshold: Senator Ben Sasse's Journey with Stage IV Cancer 09:54 – Family, Faith and Survival - Sasse's 60 Minutes Interview24:40 – Poem: "Death Is Nothing at All" by Rev. Henry Scott Holland 27:15 – Outro Support the show

Pancreatic cancer is among the most deadly forms of cancer, and it can be difficult to catch early. But there's some good news: Clinical trials of a new drug called daraxonrasib found that it doubled the survival time of patients with advanced pancreatic cancer. And some oncologists are calling it a game changer—not just for pancreatic cancer, but potentially other forms of cancer too. Ira talks with oncologist Zev Wainberg, who led a clinical trial for the drug.  Plus, ALS is a degenerative disease that causes patients to lose their ability to walk, swallow and eventually to breathe. Now, there's a drug for a rare genetic form of ALS that can slow the progression or even reverse some of these symptoms. Ira talks with New York Times health and science reporter Pam Belluck about this new treatment. Guests: Dr. Zev Wainberg is a co-director of UCLA Health's GI Oncology Program. Pam Belluck is a health and science reporter for The New York Times. Other episodes you may enjoy: mRNA Vaccine For Pancreatic Cancer Continues To Show Promise How do clinical trials work, and who can participate? Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Interview with Thomas VanderMeer, MD

Daraxonrasib is not fully FDA-approved, but doctors say the program may make treatment easier to reach for some rural patients – Brad Dugai from Mathews County is one of them.

When Robert Mayer started his career in pancreatic cancer research in the 1960s, the treatment landscape of pancreatic cancer was dismal.“We had no tools, say like CT scans, to even identify or diagnose these tumors at an early time,” said Mayer. “Colonoscopy was a big deal. Making a diagnosis of a pancreatic cancer often was restricted to the presence of metastatic disease because there was no scan, no blood test that showed that there was something awry in the pancreas. It was in the back of the abdomen and that didn't change for quite some time.“The aura developed that [pancreatic cancer] was something that just you couldn't deal with.”Mayer is now the faculty vice president for Academic Affairs at Dana-Farber Cancer Institute and faculty associate dean for Admissions at Harvard Medical School, and is watching this aura is begin to change:Daraxonrasib, a pan-RAS(on) inhibitor, was shown to double overall survival in the recent RASolute-302 trial phase III clinical trial. The results were presented at the annual American Society of Clinical Oncology annual meeting on May 31. “As with other conditions that we treat, when patients [with pancreatic cancer] come, we'll be able to give them options, plans, steps,” Mayer said. “It may not necessarily be that we can cure, but we can prolong survival, enhance quality of life, reduce time that they have to come to receive toxic systemic parenteral intravenous therapy. All things that really matter so that they can go and be at high school, college graduations, family celebrations, and do all the things that they otherwise would like to do. That has never been something that happened with pancreas cancer.”But the road to developing this drug was laden with bumps, jumps, and potholes. Mayer highlighted some of the most notable mileposts on that long journey in this episode of The Cancer History Project Podcast. 

Johnny Mac shares five good news stories: Charlie the Cow, raised in a Florida 4-H program, was at risk after a weigh-in found him too skinny, but animal lover Leslie raised funds (including paying out of pocket) to buy and transport him to Bell Family Farm sanctuary in Polk City with help from donor Sarah; researchers at the Mayo Clinic developed an AI model that detects early signs of pancreatic cancer on CT scans up to three years before typical diagnosis and performed three times better than human radiologists; high school girls on a Duke of Edinburgh Award hike in Australia built an improvised stretcher and carried an injured hiker, Thomas, for hours; a family helped their son Axel set a Guinness record by sending a six-inch rainbow Slinky down 53 stairs; and a live frog found in a bag of lettuce was released into a local dam. 00:11 Saving Charlie the Cow01:33 AI Spots Pancreatic Cancer02:29 Hikers Rescue Injured Man03:48 Slinky Staircase Record04:37 Frog Found in Lettuce 5 Good News Stories is a daily podcast with five positive, uplifting news stories to brighten your day. New episodes every day. Follow on Apple Podcasts, Spotify, or wherever you listen. Part of the Caloroga Shark Media networkJohn also hosts Daily Comedy NewsUnlock an ad-free podcast experience with Caloroga Shark Media!  For Apple users, hit the banner which says Uninterrupted Listening on your Apple podcasts app. Subscribe now for exclusive shows like 'Palace Intrigue,' and get bonus content from Deep Crown (our exclusive Palace Insider!) Or get 'Daily Comedy News,' and '5 Good News Stories' with no commercials! Plans start at $4.99 per month, or save 20% with a yearly plan at $49.99. Join today and help support the show!Get more info from Caloroga Shark Media and if you have any comments, suggestions, or just want to get in touch our email is info@caloroga.com

Dr Bill Nelson and Dr Elizabeth Jaffee discuss two significant breakthroughs in pancreatic cancer. The first is daraxonrasib, a drug that has significantly prolonged survival in patients with metastatic pancreatic cancer and a new vaccine targeting mutations that cause the disease and that could potentially go as far as preventing it altogether. 

 In this episode of Onc Now, Stephen Chan, Clinical Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong, explores the evolving landscape of hepatobiliary and pancreatic cancers. From advances in translational science and precision therapies to the challenges of neuroendocrine tumour care, Chan reflects on the progress made in oncology and the breakthroughs still needed. He also discusses his work with the Hand-in-Hand Cancer Foundation, highlighting the importance of education, compassion, and holistic support for patients and their families.  Timestamps:    00:00 – Introduction    01:18 - Current Hepatobiliary and Pancreatic Landscape   03:23 - Translational Science and Patient Outcomes   05:06 - Founding the Hand-in-Hand Cancer Foundation   06:53 - Advances in Precision Cancer Therapies   08:54 – Rising Incidence of Pancreatic Cancer Post COVID-19  10:45 - President of the International Liver Cancer Association  12:46 - Challenges in Neuroendocrine Tumour Care   14:32 - Future Breakthroughs in Cancer Care   16:02 - Three Wishes for Oncology's Future 

In this episode of OncLive On Air, Zev A. Wainberg, MD, sat down with OncLive to discuss the rapidly evolving landscape of KRAS-directed therapy in pancreatic ductal adenocarcinoma (PDAC), from pan-RAS inhibition to KRAS G12D–specific strategies, and what the next several years of clinical investigation may look like for patients with this difficult-to-treat malignancy.   Wainberg is a professor of medicine at the David Geffen School of Medicine at UCLA, co-director of the UCLA GI Oncology Program, and medical director of the UCLA Pancreas Cancer Center, where he also serves as director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center. This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive

Are money problems spilling over to work? What can you do for your employees to reduce stress?  Reduce down time? What can you do for employee retention? What is a "stop for this" purchase? As an employer, how can you reduce the chance that you get asked to give advances of payroll to employees? In this week's episode of the Crushing Debt Podcast, Shawn & George talk to Barry Sanborn about the cost of employee turnover, and what to do about it. Barry is the founder of Sanborn Financial Coaching, LLC, in Joplin, Missouri. He started his business on June 1, 2021, to help clients pursue and eventually achieve their personal money goals.   Barry provides personal financial coaching services for individuals and couples. He has a degree in business from Missouri State University and is involved in two professional financial coaching organizations. Barry's specialty involves delivering financial coaching as a unique employee benefit designed to help small business owners attract and retain great workers. The employees are offered personal financial coaching services in one-hour sessions, either in-person or online, as a benefit of working at a particular company.   You can reach Barry at BarrySanborn@hotmail.com or visit his website at www.missourimoneycoach.com.  Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026 

Dr. Lorenzo Cohen, Director of the Integrative Medicine Program at The University of Texas MD Anderson Cancer Center. He's also co-lead author of a study on whether biofield therapy can impact pancreatic cancer. The study demonstrated that biofield therapy could decrease cancer cell proliferation, disrupt mitochondrial function, and reduce metastasis in both cell cultures and animal models, with results comparable to chemotherapy without the side effects. He highlights the challenges to the wider acceptance of this therapy, given the lack of understanding of its mechanism of action and awareness about this growing area of integrative medicine. Lorenzo explains, "So biofield therapies fall into this category of, let's call them treatment modalities in the field of integrative medicine. So integrative medicine can be things like acupuncture, massage, yoga, meditation, nutrition counseling, exercise, things that you could say fall outside of the conventional traditional medical treatments that are within hospital systems. Now, integrative medicine as a whole and integrative oncology in particular have had a huge uptake in hospital systems because of the evidence base in those areas that I just described. The one area that probably remains the most controversial is this area of biofield therapies or often known as energy medicine. I don't actually really like using the term energy medicine because that implies that we know it has something to do with energy, and we're actually not sure exactly what the mechanism is of these therapies. And so what are these? So many of the listeners will have heard of things like Reiki, healing touch, or therapeutic touch."   "External Qigong falls into this category. These are modalities where a practitioner has been trained to be able to work with their own consciousness or their own intention, potentially the biofield of their body. And it is not controversial to know that we as human beings are energetic beings, and we actually do emit biophotons by the nature of being human. But the controversial part is that they are doing that towards a target, whether that be a human being, or, in our case, cells or animals in a laboratory.  And we, in particular, worked with a biofield therapy called the Bengston Cycling Method." #MDAnderson #IntegrativeOncology #BiofieldTherapy #PancreaticCancer #Metastasis #FOXM1 #Mitochondria #PreclinicalResearch #EnergyMedicine #OncologyResearch.  Biofield Therapy Anticancer Living: Transform Your Life and Health with the Mix of Six Download the transcript here

Dr. Lorenzo Cohen, Director of the Integrative Medicine Program at The University of Texas MD Anderson Cancer Center. He's also co-lead author of a study on whether biofield therapy can impact pancreatic cancer. The study demonstrated that biofield therapy could decrease cancer cell proliferation, disrupt mitochondrial function, and reduce metastasis in both cell cultures and animal models, with results comparable to chemotherapy without the side effects. He highlights the challenges to the wider acceptance of this therapy, given the lack of understanding of its mechanism of action and awareness about this growing area of integrative medicine. Lorenzo explains, "So biofield therapies fall into this category of, let's call them treatment modalities in the field of integrative medicine. So integrative medicine can be things like acupuncture, massage, yoga, meditation, nutrition counseling, exercise, things that you could say fall outside of the conventional traditional medical treatments that are within hospital systems. Now, integrative medicine as a whole and integrative oncology in particular have had a huge uptake in hospital systems because of the evidence base in those areas that I just described. The one area that probably remains the most controversial is this area of biofield therapies or often known as energy medicine. I don't actually really like using the term energy medicine because that implies that we know it has something to do with energy, and we're actually not sure exactly what the mechanism is of these therapies. And so what are these? So many of the listeners will have heard of things like Reiki, healing touch, or therapeutic touch."   "External Qigong falls into this category. These are modalities where a practitioner has been trained to be able to work with their own consciousness or their own intention, potentially the biofield of their body. And it is not controversial to know that we as human beings are energetic beings, and we actually do emit biophotons by the nature of being human. But the controversial part is that they are doing that towards a target, whether that be a human being, or, in our case, cells or animals in a laboratory.  And we, in particular, worked with a biofield therapy called the Bengston Cycling Method." #MDAnderson #IntegrativeOncology #BiofieldTherapy #PancreaticCancer #Metastasis #FOXM1 #Mitochondria #PreclinicalResearch #EnergyMedicine #OncologyResearch.  Biofield Therapy Anticancer Living: Transform Your Life and Health with the Mix of Six Listen to the podcast here

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Pancreatic Cancer⁠⁠ ⁠⁠from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications

We're dropping this bonus episode because something genuinely historic happened in oncology and we couldn't wait until our regular schedule to talk about it. Dr. Mark Lewis, GI medical oncologist, pancreatic cancer survivor, and one of our absolute favorite guests. He just got back from ASCO, the Super Bowl of oncology, where a new drug called daraxonrasib received one of only about six standing ovations in the conference's history, including applause that broke out mid-sentence when researchers showed the survival data on-screen. The drug targets a mutation that drives the vast majority of pancreatic cancer and has been considered "undruggable" for decades and it works not by attacking the mutation directly, but by cutting off the downstream signals it sends, like snipping the wire instead of fighting with the switch. The results are remarkable. In patients who had already received standard chemotherapy, daraxonrasib roughly doubled survival time and delivered it in pill form rather than an IV every two weeks, a meaningful quality-of-life difference for people who are already facing the hardest year of their lives. Mark walks us through the science, the side effects (rash, because RAS proteins live in skin too), the path to FDA approval, and what this means beyond pancreatic cancer, the same KRAS mutations show up in about 30% of lung cancers and 40% of colon cancers. Takeaways: Pancreatic cancer has been devastatingly hard to treat, 85% of patients are incurable at diagnosis because it spreads silently and there's no good screening, leaving most patients with a median survival of about a year on IV chemotherapy. KRAS, the mutation driving nearly all pancreatic cancer, was long considered "undruggable", the protein was so smooth and spherical that no drug could bind to it, and researchers were actively discouraged from pursuing it as a target. Daraxonrasib works by cutting the power rather than fighting the switch, instead of binding to the KRAS protein itself, it uses molecular glue to interrupt the downstream growth signals the mutation sends, an approach that took decades to develop and wasn't taken seriously until now. The trial results roughly doubled survival and the treatment is a daily pill, not an IV, patients who had already been treated with chemotherapy gained approximately an additional year of life with improved quality of life, which represents one of the most significant advances in pancreatic cancer treatment in decades. This breakthrough has implications far beyond the pancreas, KRAS mutations drive about 30% of lung cancers and 40% of colon cancers too, and proving the target is druggable opens the door to a new generation of treatments across multiple cancer types. Want more Dr. Mark Lewis? X: @marklewismd To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://glaucomflecken.com/glauc-to-me/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you are interested in buying a book from one of our guests, check them all out here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/dr.glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anatomywarehouse.com/?aff=14⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information.  Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

What are some of your more expensive habits? What impact does summer have on your spending? In this week's episode of the podcast, Shawn & George talk about summer's most expensive habits, including: Weddings / Vacations / Family Outings Summer Camps & Kids Activities Concerts Home Improvement Projects Pets Subscriptions Back to School Shopping Cost of Living Changes What other summer spending habits do you have? Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team (until June 30, 2026) at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026

In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute.   We discussed: The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients. The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug, Daraxonrasib. The mechanism of action of Daraxonrasib as a RAS-on inhibitor and its unique properties compared to other RAS inhibitors. Common side effects associated with the drug, including rash, diarrhea, and stomatitis, and strategies for managing these in clinical practice. The importance of biomarker testing and the implications for treatment in all pancreatic cancer patients.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Tune in to learn how this new therapy could change the landscape of treatment for pancreatic cancer patients. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in cancer research and treatment! #PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers

Your body is a buffet. Don’t let cancer put you out of business!

BUFFALO, NY – June 8, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 3, 2026, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation.” The study was led by first author Kweku Ofosu-Asante and corresponding author Nazarius S. Lamango from the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health in Tallahassee, Florida. Pancreatic ductal adenocarcinoma is among the deadliest forms of cancer, due in large part to the high frequency of KRAS mutations that drive tumor growth and resistance to treatment. Although targeted therapies have recently been developed for specific KRAS mutations, many patients continue to have limited treatment options, highlighting the need for broader strategies capable of targeting multiple KRAS-driven cancers. In this study, researchers investigated a class of experimental compounds known as polyisoprenylated cysteinyl amide inhibitors (PCAIs), which were originally designed to disrupt abnormal KRAS signaling. Using pancreatic cancer cell lines carrying KRAS mutations, the team explored how these compounds affect cancer cell survival, migration, invasion, and the molecular pathways that regulate tumor growth. Full press release - https://www.oncotarget.com/news/pr/experimental-compounds-trigger-cancer-cell-death-in-kras-driven-pancreatic-cancer/ DOI - https://doi.org/10.18632/oncotarget.28879 Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu Abstract video - https://www.youtube.com/watch?v=asbhjME7rFQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28879 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCAIs, PDAC, MAPK, PI3K/AKT, KRAS To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

#thismorning | #Molecule to #Medicine: How Daraxonrasib is #Rewriting Pancreatic #Cancer #Drug #Development | Andrew R. Snyder, PhD., Monash University | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness

Pancreatic Cancer Halted by Virus Injection Researchers injected an engineered virus directly into pancreatic tumors in three patients — the virus replicated inside malignant cells, triggered an immune response, and stopped tumor growth and spread at an intentionally low early dose. Host Dave Asprey breaks down why oncolytic viruses can do what chemotherapy can't, how the tumor's dense biological wall becomes less of an advantage when a virus can replicate inside it directly, and why a measurable response at a safety dose is the kind of early signal that changes how he's watching this field. Sources: https://www.newscientist.com AI Chatbots and Teen Mental Health A new survey shows roughly one in five adolescents and young adults are now going to AI chatbots when they feel sad, anxious, nervous, or stressed, with usage heaviest in the 18–21 range. Host Dave Asprey explains why general-purpose language models designed to be engaging are dangerous as a substitute for real mental health support, why false reassurance from a chatbot may make the pipeline to real care harder to reach, and why this is a health systems story masquerading as a tech adoption story — and what parents need to do about it. Sources: https://www.nbcnews.com GLP-1 Drugs Cut Breast Cancer Risk Penn Medicine published a retrospective analysis of over 111,000 women finding GLP-1 exposure associated with about 35% lower odds of breast cancer in the full cohort and around 30% lower in a matched comparison group. Host Dave Asprey breaks down why this isn't just a weight loss story — it's a metabolic dysfunction story — explains the insulin resistance, inflammation, and hormonal environment mechanisms that may be driving the signal, and makes the case that this finding should be reshaping how oncologists and OBGYNs think about high-risk patients right now. Sources: https://www.pennmedicine.org Putin's $26 Billion Longevity Program The Wall Street Journal reports that Russia has made anti-aging research a Kremlin-level national priority through a $26 billion program including gene therapy, organ bioprinting, and xenotransplantation, led by Putin's daughter Maria Vorontsova and physicist Mikhail Kovalchuk. Host Dave Asprey breaks down what's geopolitical theater, what's legitimately frontier science, and why the real question is whether any findings will make it out to the broader research community or get locked inside a state program. Sources: https://www.wsj.com https://www.france24.com Sauna vs. Cold Plunge A landmark Finnish study tracked over 2,300 men for nearly 21 years and found increasing sauna frequency associated with dramatically lower cardiovascular and all-cause mortality — strongest at four or more sessions per week. Host Dave Asprey settles the debate with the actual data, explains what heat shock proteins and cold shock proteins actually are and why the evidence base behind them is nowhere near equivalent, and calls out the wellness marketing presenting early-stage mouse model research as the cold water equivalent of two decades of human mortality outcomes. Sources: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2521522 This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on cancer treatment breakthroughs, adolescent mental health and AI, metabolic drivers of disease, geopolitical longevity science, and the real evidence behind popular recovery modalities. Host Dave Asprey connects emerging clinical research, objective epidemiological data, and real-world optimization protocols into actionable frameworks for extending healthspan, sharpening performance, and staying ahead of the science. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: oncolytic virus pancreatic cancer, engineered virus tumor treatment, AI chatbot teen mental health, adolescent AI emotional support, GLP-1 breast cancer risk, semaglutide cancer prevention, metabolic dysfunction root cause disease, Putin longevity program Russia, New Health Preservation Technologies, anti-aging biotech geopolitics, sauna longevity mortality data, cold plunge cold shock proteins, RBM3 heat shock proteins, sauna vs cold plunge evidence, biohacking news 2026, longevity research, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Suppgrade Labs | Grab your DAKE and Minerals 101 duo at shopsuppgradelabs.com and use code DAVEPOD for 15% off today - Essentia | Go to https://myessentia.com/dave and use code DAVE for $100 off The Dave Asprey Upgrade. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:42 – Pancreatic Cancer Halted by Virus Injection 01:44 – Teens & AI Therapy Chatbots 03:13 – GLP-1 Drugs Cut Breast Cancer Risk 04:30 – Russia's $26B Longevity Program 06:18 – Sauna vs. Cold Plunge 09:10 – Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send Zorba a message!Zorba explains a breakthrough treatment for advanced pancreatic cancer that nearly doubles the survival rate.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Broadcast from KSQD, Santa Cruz on 6-04-2026: A caller with previously normal platelets now bouncing between 40-60 asks whether to accept her doctor's recommendation of high-dose dexamethasone. Dr. Dawn suggests checking homocysteine and methylmalonic acid for hidden B12 issues, getting an ultrasound to rule out splenic sequestration, and confirming actual autoimmune antibody testing before committing to steroids. Researchers invented a fake disease called "Bixonimania" (periorbital hyperpigmentation supposedly caused by blue light) with obvious tells including a fictional Asteria Horizon University and Starfleet Academy acknowledgment. By 2026, AI chatbots were routinely describing it as real, and three Indian researchers even cited the fake preprint in a peer-reviewed paper that was subsequently retracted. A 75-year-old caller asks about intermittent fasting patterns. Dr. Dawn advises against fasting longer than 24 hours after age 75 due to muscle catabolism, and recommends time-restricted eating instead—starting with protein at 10am to prevent muscle breakdown. For rebuilding lost muscle she prescribes resistance bands, 30g protein including 5g branched-chain amino acids before exercise, and total daily protein matching one's age in grams. A male caller with a T-score of -4.0 on DEXA (diagnostic of severe osteoporosis) asks about pulsed electromagnetic frequency therapy for his hip. Dr. Dawn explains bone's piezoelectric properties mean that compression and electrical stimulation both activate osteoblasts. She recommends checking parathyroid hormone (tumors cause silent calcium loss), notes that vitamin D above 10,000 IU daily can paradoxically activate osteoclasts and worsen osteoporosis. She discusses how decades of proton pump inhibitor use cause achlorhydria leading to both B12 deficiency (elevated MCV) and calcium malabsorption. The same caller asks whether AI has genuine empathy after seeing Claude express regret about military use, and Dr. Dawn explains AI is a statistical mirror — the illusion of empathy from frequency-based word selection trained on human text, not genuine feeling. Daraxonrasib, an oral monoclonal drug from Revolution Medicines, doubled survival time in metastatic pancreatic cancer trials from 7 to 13 months, prompting FDA expanded access. Dr. Dawn explains KRAS—the long-elusive target with no binding pockets—was finally tackled using Gregory Verdine's "molecular glue" approach, where small molecules first attach to bystander proteins to create complexes capable of binding KRAS. A high school in San Francisco has seen seven active and 241 latent TB cases since November 2025, with 18% of the school community infected. Dr. Dawn notes California reached a 12-year high of 2,150 TB cases in 2025, and connects the unusually high latent-infection rate to recent Medi-Cal cuts and immigration-related healthcare avoidance. She argues healthcare access for vulnerable populations is a practical disease-prevention measure.

Send Zorba a message!Zorba explains a breakthrough treatment for advanced pancreatic cancer that nearly doubles the survival rate.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

It is officially  the start of Hurricane Season in Florida! Are you prepared? What are some funny hurricane truths? How much water should you have?  Toilet paper? Flash lights and batteries? How should you prepare your family and your business for the financial impact of a storm? On this week's episode of The Crushing Debt Podcast, Shawn & George talk about these topics, including whether you are financially ready personally and professionally for a storm, what you need to know or do to protect your family and your business, all with our unique Crushing Debt spin! Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026. The link will be open through the end of June!

SMH's Kolschowsky Research and Education Institute is enrolling patients in a research study evaluating LINFU (Low-Intensity Non-Focused Ultrasound), an emerging screening technology designed to help doctors identify precancerous changes in people at high risk for pancreatic cancer, but who have no signs or symptoms of the disease. Kenneth Meredith, MD, chief of gastrointestinal oncology at SMH's Brian D. Jellison Cancer Institute and principal investigator of the local study, says the screening represents an important step forward in pancreatic cancer research. You can also watch the video recording on our Vimeo channel here. For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Headlines: – Welcome to Mo News + Taylor Swift ‘Toy Story' Single (02:00) – Florida Sues OpenAI and Sam Altman Over AI Risks For Kids (04:30) – Claude Maker Anthropic Files For IPO, Setting Up Public-Market Test Of AI Boom (08:20) – US Bombs Iranian Military Sites,Then Downs Missiles Tehran Fired At Troops In Kuwait (12:00) – Iran Warns Israeli Attacks In Lebanon Threaten Ceasefire With US; Trump Says “Shooting Will Stop” (18:00) – Why The Trump Administration Plans To Drop Its "Weaponization" Fund (20:45) – Pancreatic Cancer 'Miracle' Drug Daraxonrasib Doubles Survival Rate In New Trial (25:00) – Scott Pelley Accuses CBS News Boss of ‘Murdering' ‘60 Minutes' (28:30) – Judge Rules Charlie Kirk Suspect's Hearing Will Be Open To The Public (38:00) – Serena Williams Returns to Pro Tennis After Four-Year Hiatus (40:10) – On This Day In History (45:00) Thanks To Our Sponsors: – Monarch - 50% off your first year | Code: MONEWS – Factor - 50% off your first box | Code: monews50off –⁠ Industrious⁠ - Coworking office. 50% off day pass | Code: MONEWS50 – LMNT | Free Sample Pack with any LMNT drink mix or 12oz cans purchase

Oncologist Austin Duffy discusses the development of a new daily drug for panceatic cancer.

⚡ Myoscience Electrolyte Sticks with Creatine — 20% off exclusively for Ben's audience : https://bit.ly/4efbmfS 

A medical breakthrough in the fight against pancreatic cancer is showing promising results after decades of research. The experimental drug, taken once a day, extends patients' lives by slowing the progression of one of the deadliest cancers. Dr. Rachna Shroff, associate director of clinical investigations at the University of Arizona Comprehensive Cancer Center, joins Stephanie Sy for more. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

The CEO of Kalshi joins to discuss the company's latest product announcements and the regulatory environment for prediction markets. Then, Former Defense Secretary Mark Esper helps break down the latest headlines on the war with Iran. We also speak with the CEO of D-Wave Quantum following the U.S. government's recent investment in quantum companies. Plus, the CEO of Revolution Medicines joins to discuss the company's pancreatic cancer drug that nearly doubled survival rates.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively. Topics Covered: Overview of the RASolute-302 study Impact of Daraxonrasib on overall survival RAS mutations in pancreatic cancer Mechanism of action of RAS inhibitors Side effects and management strategies Tune in now for an enlightening discussion on the future of pancreatic cancer treatment! #ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

CBC News has a draft copy of the federal government's long-delayed strategy on artificial intelligence. It's promising to create up to 90,000 jobs, protect Canadians against the risks of AI, and massively boost the number of businesses that use it.And: A new drug for pancreatic cancer is showing unprecedented promise. In a trial, it doubled survival time for patients who had already gone through one round of chemotherapy. It's not on the market yet, but it is a sign of progress in treating one of the deadliest forms of cancer.Also: It's one of the fastest growing games in Canada. But the organization in charge of cricket in this country is under increasing fire. The sport's international governing body has suspended its membership after an investigation by CBC's The Fifth Estate put a spotlight on issues of corruption and allegations of match fixing.Plus: Prime Minister Carney outlines plan to deal with antisemitism, U.S.-Iran negotiations, and more.

Medical researchers are hailing a new drug to treat the world's most deadly cancer as the biggest breakthrough in decades. Auckland University's Associate Professor of Oncology, Dr Ben Lawrence spoke to John Campbell.

AP correspondent Donna Warder reports on a pill that's helping some patients with advanced pancreatic cancer live longer.

Why do people think bankruptcy is bad? True, it has a negative stigma and it will be a hit to your credit score, but why is bankruptcy perceived as a massive negative? Is bankruptcy the best solution for everyone?  Put simply, no it is not, but it is better than most people will admit. On this week's episode of The Crushing Debt Podccast, Shawn and George talk about rising debt levels, rising gas prices, rising grocery prices ... prices increasing everywhere, and what that means for someone considering bankruptcy. Plus what are some of the negatives of waiting too long to file?  What is the difference between bankruptcy and negotiating the debt? What is the impact of the automatic stay?  And what is life like after bankruptcy? Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And there is still time, until June 30, 2026 to donate to Pancreatic Cancer research and education by joining Shawn's 2026 PanCAN team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026

Pancreatic cancer is a devastating diagnosis, and the statistics are alarming. According to the latest research, it's the third leading cause of cancer-related deaths in the US, with over 50,000 people losing their lives each year. The disease is particularly aggressive, with a survival rate of just six to seven months after diagnosis. In this episode, our guest, Dr. Greg Verdine, shares his insights on a promising new treatment that could reshape the way we approach pancreatic cancer. Dr. Verdine, a professor of chemistry at Harvard and CEO of LifeMine Therapeutics, discusses the challenges of treating pancreatic cancer, including its tendency to be asymptomatic until late stages and its resistance to chemotherapy. He explains how a new daily pill, currently in early trial stages, targets the cancer's genetic mutations and has shown promising results in extending patients' lifespans. The conversation delves into the complexities of pancreatic cancer, including its unique characteristics that make it difficult to treat. Dr. Verdine highlights the importance of this new treatment, which has the potential to double patients' lifespans and pave the way for further research. If you're interested in learning more about this breakthrough treatment and the future of pancreatic cancer research, tune in to this episode to hear Dr. Verdine's expert insights and the potential for a brighter outlook on this devastating disease.See omnystudio.com/listener for privacy information.

A Huntington Beach, California, high school senior honors her dying father by holding an early graduation for herself, fulfilling both their wishes. AND Tragedy hit my own Tennessee community on March 27, 2026, when a middle school bus on a field trip got into an accident. To see videos and photos referenced in this episode, visit GodUpdates! https://www.godtube.com/blog/high-school-senior-honors-dying-father.html https://www.godtube.com/blog/church-helping-community-after-bus-crash.html Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

What if “energy healing” could be tested—and measured—in a world-class cancer research setting?In this episode of Unpacking Possibility, host Traci Stein unpacks a groundbreaking MD Anderson Cancer Center preclinical study investigating biofield therapy (energy healing) and its reported effects on pancreatic cancer in lab and animal models—including slower growth and spread.Traci shares the findings of this study and discusses them in the broader context of research on biofield therapies (including Reiki, Healing Touch, and Therapeutic Touch). She also shares a personal story about doing Reiki in an operating room for a patient who was undergoing heart surgery and how what she witnessed deepened her perspective on subtle energy. You'll also learn a simple, at-home exercise you can try to begin sensing your own energy field (as well as a friend's).In this episode you'll learn more about:- What the MD Anderson studies found- Why pancreatic cancer research needs new possibilities - Early research showing energy healing could make seeds germinate faster, surgical wounds heal better, and more- A brief look at the Bengston Healing Method and “image cycling” - A simple exercise you can try tonight to explore energy-field sensing Note: This episode is educational and not medical advice. Always consult your healthcare team about diagnosis and treatment.To learn more about Traci's self-paced, online course, “Developing Everyday Intuition,” visit: https://www.drtracistein.com/developing-everyday-intuition-courseTo receive $5 off the price of Traci's course, “Developing Everyday Intuition,” apply code ENERGY5OFF before checkout.“The Everything Guide to Integrative Pain Management,” by Traci Stein, PhD, MPH: https://a.co/d/0fji41kQTo read the MD Anderson paper: https://onlinelibrary.wiley.com/doi/10.1002/cam4.71726

Join us as we review recent articles and news featured in The DIGEST, including updated lipid guidelines, GLP1 agonists holds and procedures, the newest drug in pancreatic cancer, and discontinuing thyroid supplementation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Nora Taranto (@norataranto), Laura Glick (@lauraglick) and Matt Watto (@doctorwatto).Claim free CME for this episode at curbsiders.vcuhealth.org!Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME!Credits Written and Hosted by: Nora Taranto MD MSCE, Laura Glick MD,  Matthew Watto MD, FACP Cover Art:  Nora Taranto MD MSCE Reviewers: Emi Okamoto MD  Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro and pun   Lipid Management Guidelines Overview  Emerging Treatments in Oncology  Press Release on a new KRAS Inhibitor for Pancreatic Cancer  Perioperative Considerations for GLP-1 Use  Deprescribing Levothyroxine in Older Adults Sponsor: Panacea FinancialIf you're about to make the leap into  residency and feeling the financial pressure of that transition, visit  PanaceaFinancial.com/curbsiders today. Sponsor: UpToDatefor a limited time, get 10% off UpToDate packages with code CURB10. Visit store.uptodate.com to save on your annual or longer personal UpToDate subscription today. 

The pandemic triggered something unexpected:  American fathers started working less and spending significantly more time on childcare and housework — and new research suggests it wasn't remote work or job loss driving the shift, but a genuine realignment of gender norms. Plus: some scientists are calling this the biggest advancement in cancer treatment in 15 years – a drug called daraxonrasib which is nearing FDA approval and substantially extends the lives of pancreatic cancer patients; Brazil has officially begun demarcating over a million acres of protected land for an uncontacted Indigenous tribe in the Amazon; and Oklahoma became the 17th U.S. state to ban child marriage, ruffling some feathers.  What Could Go Right? is produced by The Progress Network and Kaleidoscope. For transcripts, to join the newsletter, and for more information, visit: theprogressnetwork.org Subscribe to our (FREE) Substack newsletter: https://theprogressnetwork.org/newsletter/ Watch the podcast on YouTube: / theprogressnetwork Follow us on X, Instagram, Facebook, TikTok: @progressntwrk Follow Emma on Instagram: https://www.instagram.com/heyemmavarv/

Broadcast from KSQD, Santa Cruz on 5-21-2026: This is the second show featuring Mira Achilles, a UCSC graduate working on her masters in epidemiology. Dr. Dawn and Mira open with a Harvard study showing OpenAI's o1 reasoning model reached correct diagnoses 67% of the time versus 50-55% for physicians, and scored 89% versus 34% on treatment plans. The AI advantage shrinks when doctors get more data and time, suggesting its greatest value is in fast-moving triage. Dr. Dawn cautions that over-reliance on AI during residency could undermine the clinical reasoning neurologic pathways doctors must develop, and emphasizes the "zebra paradox"— rare diseases remain rare even when symptoms match the textbook. Dr. Dawn shares a personal case of a patient with throat shingles, leading her to use a medical AI (OpenEvidence) to investigate Shingrix risks. An Australian study found an elevenfold increase in shingles within 21 days of the first Shingrix dose in adults over 65, though dose two reduced overall risk by 73%. She explains this could be one of several things such as immune reconstitution inflammatory syndrome (IRIS), or that the AS01B vaccine adjuvant's strong activation may transiently reactivate latent virus, and recommends valacyclovir prophylaxis for high-risk patients for their first Shringrex shot.. Mira discusses AI in education, noting the shift from professors threatening plagiarism charges to teaching students how to critique AI output, emphasizing taking summaries "with a grain of salt." Dr. Dawn describes Chinese research scanning 1,154 children that identified a third ADHD subtype—severe emotional dysregulation—showing 45 abnormal brain regions versus 26 in the inattentive and hyperactive-impulsive types, with standard stimulants working poorly for this group. She connects this to traditional psychiatric personality disorder classifications and A discussion of vagus nerve stimulation's emerging applications for autoimmune conditions. Dr. Dawn and Mira discuss menstruation and bodily autonomy, then describe the Somedays period pain simulator that uses electrical impulses to let men experience menstrual cramps, highlighting differing pain thresholds. An emailer references a Radiolab episode about deliberate hookworm infection to treat asthma and allergies. Dr. Dawn explains parasites release immunosuppressants to survive, including anti-inflammatory protein-2 (AIP) now in drug development, which stimulates T-regulatory cells and IL-10 while "alarmins" inhibit lung inflammation—though this increases vulnerability to new infections. A caller with H. pylori and frequent viral infections asks whether S. boulardii and reuteri probiotics are safe given her low immunity. Dr. Dawn explains immunosuppression warnings target transplant-level drug suppression, not a tendency toward viruses like hers. Dr. Dawn thinks that her near-zero natural killer cells explain frequent infections, and suggests that the H. pylori test given her absence of symptoms, may be an incidental bystander rather than the cause of her low ferritin, which suggests bleeding. In medical news of the weird, Dr. Dawn describes Baby Cassian, diagnosed in utero with congenital high airway obstruction syndrome (CHAOS), who was partially removed from the womb at 25 weeks for airway surgery, returned, and born again at 31 weeks—leading to a discussion of microsurgery and how specialties partition by the physical scale of the surgery rather the location or type of structure.